SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: PRE 14A
Document Type: PRE 14A
Date Filed: 2025-04-17
Accession Number: 0001213900-25-032976
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025032976/ea0238236-01.htm

Chunk 7 of 16
Word Count: 1492
Character Count: 9488

Document Content:

Plan modifications are not effective until the 31st day after adoption. The purpose of these plans Table of Contents is to enable executive officers to recognize the value of their compensation and diversify their holdings of our stock during periods in which the executive officer or director would be unable to sell our common stock because material information about us had not been publicly released. Our insider trading policy prohibits our Board members, officers, employees and consultants from purchasing Company securities on margin, borrowing against Company securities held in a margin account, or pledging Company securities as collateral for a loan. However, in extraordinary situations where a person wishes to pledge Company securities as collateral for a loan (other than a margin loan) and can clearly demonstrate the financial capacity to repay the loan without resort to the pledged Company securities, an exception may be granted. Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our officers, directors and any persons who own more than 10% of our Common Stock to file reports of ownership of, and transactions in, our Common Stock with the SEC and furnish copies of such reports to us. Based solely on our reviews of the copies of such forms and amendments thereto furnished to us and on written representations from officers, directors, and any other person whom we understand owns more than 10% or our Common Stock, we found that during 2024, all Section 16(a) filings were made with the SEC on a timely basis except that one Form 4 covering fifty four transactions was filed late for Mr. Ross.

Stockholder Communications to our Board of Directors

Generally, stockholders who have questions or concerns should contact our Investor Relations department at snyr@gateway-grp.com. However, any stockholders who wish to address questions regarding our business directly with the board of directors, or any individual director, should direct his or her questions in writing to Synergy CHC Corp., at 865 Spring Street, Westbrook, Maine 04092, Attn: Corporate Secretary or by using the “Contact” page of our website www.investors.synergychc.com/contact-ir. Communications will be distributed to the board of directors, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the communications. Items that are unrelated to the duties and responsibilities of the board of directors may be excluded, such as:

•        junk mail and mass mailings;

•        resumes and other forms of job inquiries;

•        surveys; and

•        solicitations or advertisements.

In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any outside director upon request.

Executive Officers

The following table sets forth certain information as of April 17, 2025, regarding our executive officers. Information regarding our Chief Executive Officer, Jack Ross, and our President, Alfred Baumler, can be found under the caption “The Board of Directors” above.

Name Age Position

Jaime Fickett 46 Chief Financial Officer

Jaime Fickett has served as our Chief Financial Officer since December 2024. Previously, Ms. Fickett served as our Senior Vice President of Finance and Operations since January 2015. From August 2006 to January 2015, Ms. Fickett served as Chief Financial Officer of Factor Nutrition Labs, LLC, a company that developed dietary supplements. From 1999 to 2006, Ms. Fickett was employed in the public accounting sector as an auditor. Ms. Fickett earned a Bachelor of Science in Accounting from the University of Maine. Ms. Fickett earned her Master of Science in Accounting from Southern New Hampshire University.

Table of Contents

EXECUTIVE OFFICER AND DIRECTOR COMPENSATION

This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers. Our Compensation Committee will review and approve the compensation of our executive officers and oversee our executive compensation programs and initiatives.

Summary Compensation Table

Fiscal Year 2024 and 2023 Summary Compensation Table

The following Fiscal Year 2024 and 2023 Summary Compensation Table contains information regarding compensation for 2024 and 2023 that we paid to Mr. Ross and our two other most highly compensated executive officers as of December 31, 2023.

Name and Principal Position Year Salary ($) Bonus ($) All other compensation ($) Total ($)

Jack Ross 2024 1,321	​ (2) — 1,321

Chief Executive Officer and Chairman (1) 2023 500,000	​ (2) — 20,000	​ (3) 520,000

Alfred Baumeler 2024 349,993 — 48,740	​ (4) 398,733

President 2023 349,993 — 48,977	​ (4) 398,970

Jaime Fickett 2024 379,493 — 13,737	​ (5) 393,230

Chief Financial Officer (6) 2023 379,493 — 13,712	​ (5) 393,204

(1)      Mr. Ross serves as our Chief Executive Officer and Chairman, and is not an employee of the Company.

(2)      Consists of amounts paid to Kenek Brands Inc., a related party.

(3)      Consists of a vehicle allowance of $2,500 per month for eight months.

(4)      Consists of a vehicle allowance of $600 per month, a retirement allowance of $7,500 and a health insurance allowance of $34,040 and $34,277, for 2024 and 2023, respectively.

(5)      Consists of a health insurance allowance of $13,737 and $13,712 for 2024 and 2023, respectively.

(6)      Effective as of December 6, 2024, Ms. Fickett was appointed Interim Chief Financial Officer of the Company. Ms. Fickett was appointed Chief Financial Officer of the Company on March 27, 2025.

Consulting Agreement

The following discussion relates to compensation arrangements on behalf of, and compensation paid by us to an entity controlled by Mr. Ross. We do not have an employment agreement with Mr. Baumeler or Ms. Fickett.

We are party to a Sales and Marketing Consultant and Distribution Agreement dated April 2, 2014 (the “Consulting Agreement”) with Kenek Brands Inc. (“Kenek”). Mr. Ross is the owner of Kenek and its sole officer and director. Pursuant to the Consulting Agreement, Kenek has been retained to serve as a consultant and advisor to us, including developing, expanding and managing sales, marketing and distribution and aiding in strategic direction of our sales and planning. As compensation for Kenek’s services, we pay Kenek $9,000 per month plus a 2% commission on all product sales on products that Kenek or its agents or brokers introduce to us. In addition, on April 2, 2014, we granted Kenek fully-vested options to purchase 84,034 shares of our common stock at an exercise price of $2.98 per share, which have expired. We have also agreed to reimburse Kenek for all out-of-pocket expenses incurred to perform the duties set out in the Consulting Agreement, including travel, meals and lodging. The Consulting Agreement had an initial period of one year and automatically renews for successive one-year periods unless terminated by either party upon 90 days’ prior written notice. For two years following termination, we have agreed to pay to Kenek a 1% commission on all product sales on products that Kenek or its agents or brokers introduced to us. See “Certain Relationships and Related Party Transactions” for additional information.

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

The following table lists all of the outstanding equity awards held on December 31, 2024 by each of the Company’s named executive officers, giving effect to the 1-for-11.9 reverse stock split that was effected on September 11, 2024.

Name Option Awards Stock Awards

Number of securities underlying unexercised options exercisable (#) Number of securities underlying unexercised options unexercisable (#) Equity incentive plan awards: Number of securities underlying unexercised unearned options (#) Option exercise price ($) Option expiration date Number of shares or units of stock that have not vested (#) Market value of shares of units of stock that have not vested ($) Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($)

Jack Ross — — — — — — — — —

Alfred Baumeler 84,034 — — 7.74 12 / 14 / 2025 — — — —

Jaime Fickett 84,034 — — 7.74 12 / 14 / 2025 — — — —

Pay Versus Performance

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid to our principal executive officer (“PEO”) and the other named executive officers (“NEOs”), as calculated in accordance with Item 402(v) of Regulation S-K, and certain financial performance measures. In accordance with the transitional relief under the SEC rules for smaller reporting companies, only two years of information is required as this is the Company’s first year of disclosure under Item 402(v) of Regulation S-K.

Pay Versus Performance Table

Year Summary Compensation Table Total for PEO (1) Compensation Actually Paid to PEO (2) Average Summary Compensation Table Total for Non-PEO NEOs (3) Average Compensation Actually Paid to Non-PEO NEOs (2) Value of Initial Fixed $100 Investment Based on Total Shareholder Return Net   Income